natgillin/translations-raw huggingface dataset:
There is no specific antidote for overdose with pazopanib and treatment of overdose should consist of general supportive measures. 
Zdravljenje v primeru prevelikega odmerjanja mora vključevati splošne podporne ukrepe.
Blurry or impaired vision 
Zamegljen vid ali okvara vida
In repeat dose studies in rodents, effects in a variety of tissues (bone, teeth, nail beds, reproductive organs, haematological tissues, kidney and pancreas) appear related to the pharmacology of VEGFR inhibition and/or disruption of VEGF signalling pathways, with most effects occurring at plasma exposure levels below those observed in the clinic. 
Pri študijah s ponavljajočimi se odmerki pri glodavcih so bili učinki na različna tkiva (kosti, zobje, nohtni matriks, reproduktivni organi, hematološko tkivo, ledvice in trebušna slinavka) v skladu s farmakološkim delovanjem, to je zaviranjem receptorjev za žilni endotelijski rastni faktor (VEGFRVascular Endothelial Growth Factor Receptors) in/ali motenjem signalnih poti za žilni endotelijski rastni faktor.
Pooled data from the pivotal STS study (VEG110727, n=369) and the supportive Phase II study (VEG20002, n=142) was evaluated in the overall evaluation of safety and tolerability of pazopanib (total safety population n=382) in subjects with STS (see section 5.1). 
faze (VEG20002, n = 142) so bili ovrednoteni v celotni oceni varnosti in prenašanja pazopaniba (skupna populacija glede varnosti n = 382) pri preiskovancih s STS (glejte poglavje 5.1).
Table 7 Median steady-state pazopanib pharmacokinetics measured in subjects with hepatic impairment. 
Preglednica 7 Mediane farmakokinetike pazopaniba v stanju dinamičnega ravnovesja pri bolnikih z okvaro jeter
Figure 5 Kaplan-Meier Curve for Progression-Free Survival in STS by Independent Assessment for the Overall Population (VEG110727) 
Slika 5 Kaplan-Meierjeva krivulja za preživetje brez napredovanja pri STS za celotno populacijo po neodvisni oceni (VEG110727)
Signs and symptoms may include: - sharp chest pain - shortness of breath - rapid breathing - leg pain - swelling of your arms and hands or legs and feet 
Znaki in simptomi lahko vključujejo: - ostro bolečino v prsih, - kratko sapo, - hitro dihanje, - bolečino v nogah, - zatekanje rok in dlani ali nog in stopal.
Very common Decreased appetite Hypoalbuminemia f 
Presnovne in prehranske motnje zelo pogosti zmanjšan apetit hipoalbuminemija f pogosti dehidracija občasni hipomagneziemija 1
Abdominal pain, abdominal pain upper and abdominal pain lower b Oedema, oedema peripheral, eye oedema, localised oedema and face oedema c 
Bolečine v trebuhu, bolečine v zgornjem delu trebuha in bolečine v spodnjem delu trebuha b Edemi, periferni edemi, edemi oči, lokalizirani edemi in edem obraza c
Common Musculoskeletal pain 35 (9%) Myalgia Muscle spasms Uncommon Arthralgia 
Bolezni mišičnoskeletnega sistema in vezivnega tkiva pogosti mišično-skeletne bolečine 35 (9 %) mialgija mišični krči občasni artralgija
- increase in the number of red blood cells - sudden shortness of breath, especially when accompanied with sharp pain in the chest and /or rapid breathing (pulmonary embolism) - severe bleeding in the digestive system (such as stomach, oesophagus or intestine), or the kidneys, vagina and brain - heart rhythm disturbance (QT prolongation) - hole (perforation) in stomach or intestine - abnormal passages forming between parts of the intestine (fistula) - heavy or irregular menstrual periods - sudden sharp increase in blood pressure (hypertensive crisis) - inflammation of the pancreas (pancreatitis) - liver inflamed, not working well or damaged - yellowing of the skin or whites of the eyes (jaundice) - inflammation of the lining of the abdominal cavity (peritonitis) - runny nose - rashes which may be itchy or inflamed (flat or raised spots or blisters) - frequent bowel movements - increased sensitivity of the skin to sunlight - decreased feeling or sensitivity, especially in the skin 
- povečano število rdečih krvnih celic, - nenadno težko dihanje, zlasti če ga spremlja ostra bolečina v prsih in/ali hitro dihanje (pljučna embolija), - huda krvavitev v prebavilih (npr. v želodcu, požiralniku ali črevesu), ledvicah, nožnici ali možganih, - motnje srčnega ritma (podaljšanje intervala QT), - predrtje (perforacija) želodca ali črevesa, - nenormalna povezava med dvema deloma črevesa (fistula), - močne ali neredne menstruacije, - nenadno, močno zvišanje krvnega tlaka (hipertenzivna kriza), - vnetje trebušne slinavke (pankreatitis), - vnetje, slabo delovanje ali okvara jeter, - rumeno obarvanje kože ali očesnih beločnic (zlatenica), - vnetje mrene, ki pokriva trebušno votlino (peritonitis), - izcedek iz nosu, - izpuščaji, ki so lahko srbeči ali vneti (ploščate ali dvignjene lise ali mehurji), - pogosto iztrebljanje, - večja občutljivost kože za svetlobo, - zmanjšano zaznavanje ali občutljivost, zlasti na koži.
Signs and symptoms of a hypertensive crisis may include: - severe chest pain - severe headache - blurred vision - confusion - nausea - vomiting - severe anxiety - shortness of breath - seizures (fits) - fainting 
Znaki in simptomi hipertenzivne krize lahko vključujejo: - hudo bolečino v prsih, - hud glavobol, - zamegljen vid, - zmedenost, - siljenje na bruhanje, - bruhanje, - hudo zaskrbljenost, - kratko sapo, - epileptični napad (krče), - omedlevico.
Grade 3 fatigue (dose-limiting toxicity) and Grade 3 hypertension were each observed in 1 of 3 patients dosed at 2000 mg and 1000 mg daily, respectively. 
V kliničnih študijah so ovrednotili uporabo pazopaniba v odmerkih do 2000 mg. Utrujenost 3. stopnje (toksični učinek, ki omejuje odmerek) oziroma hipertenzijo 3. stopnje so ugotovili pri 1 od 3 bolnikov, ki so prejemali odmerek 2000 mg oziroma 1000 mg na dan.
Co-administration of pazopanib with potent P-gp or BCRP inducers may alter the exposure and distribution of pazopanib, including distribution into the CNS. 
Sočasna uporaba pazopaniba z močnimi induktorji P-gp ali BCRP lahko spremeni izpostavljenost pazopanibu in njegovo porazdelitev, vključno s porazdelitvijo v osrednje živčevje.
- heart becomes less effective at pumping blood around the body (cardiac dysfunction) - slow heart beat - bleeding in the mouth, rectum or lung - dizziness - blurred vision - hot flushes - swelling caused by fluid of face, hands, ankles, feet or eyelids - tingling, weakness or numbness of the hands, arms, legs or feet - skin disorders, redness, itching, dry skin - nail disorders - burning, prickling, itching or tingling skin sensation - sensation of coldness, with shivering - excessive sweating - dehydration - muscle, joint, tendon or chest pain, muscle spasms - hoarseness - shortness of breath - cough - coughing up blood - hiccups - collapsed lung with air trapped in the space between the lung and chest, often causing shortness of breath (pneumothorax) 
- poslabšanje učinkovitosti srca za črpanje krvi po telesu (moteno delovanje srca), - počasno bitje srca, - krvavitev v ustih, danki ali pljučih, - omotica, - zamegljen vid, - vročinski valovi, - oteklost obraza, dlani, gležnjev, stopal ali vek zaradi tekočine, - zbadanje, šibkost ali odrevenelost dlani, rok, nog ali stopal, - spremembe na koži, rdečina kože, srbenje in suha koža, - spremembe na nohtih, - pekoč, zbadajoč, srbeč ali mravljinčast občutek v koži, - občutek hladu z mrazenjem, - prekomerno znojenje, - dehidracija, - bolečina v mišicah, sklepih, tetivah ali prsih, mišični krči, - hripavost, - težko dihanje, - kašelj, - izkašljevanje krvi, - kolcanje, - kolaps pljuč z zrakom, ujetim v prostoru med pljuči in prsnim košem; to pogosto povzroči kratko sapo (pnevmotoraks).
Concurrent administration of pazopanib (400 mg once daily) with the strong CYP3A4 and P-gp inhibitor ketoconazole (400 mg once daily) for 5 consecutive days resulted in a 66% and 45% increase in mean pazopanib AUC(0-24) and Cmax, respectively, relative to administration of pazopanib alone (400 mg once daily for 7 days). 
Sočasna uporaba pazopaniba (400 mg enkrat na dan) z močnim zaviralcem CYP3A4 in P-gp ketokonazolom (400 mg enkrat na dan) 5 dni zapored je povzročila povečanje povprečne AUC(0-24) pazopaniba za 66 % in njegove Cmax za 45 % v primerjavi z uporabo pazopaniba samega (400 mg enkrat na dan 7 dni).
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with pazopanib (see section 4.6). 
Ženskam v rodni dobi je treba pojasniti, da med zdravljenjem s pazopanibom ne smejo zanositi (glejte poglavje 4.6).
Pazopanib resulted in an increase of approximately 30% in the mean AUC and Cmax of midazolam (CYP3A4 probe substrate) and increases of 33% to 64% in the ratio of dextrometrophan to dextrophan concentrations in the urine after oral administration of dextromethorphan (CYP2D6 probe substrate). 
Pri sočasni uporabi pazopaniba sta se srednji vrednosti AUC in Cmax midazolama (preiskovani substrat za CYP3A4) povečali za približno 30 %, razmerje koncentracij dekstrometrofana in dekstrofana v urinu po peroralni uporabi dekstrometorfana (preiskovani substrat za CYP2D6) pa se je povečalo za od 33 % do 64 %.
Grade 3 n (%) 
Stopnja 3 n (%)
No significant difference in OS was observed between the two treatment arms at the final OS analysis performed after 76% (280/369) of the events had occurred (HR 0.87, 95% CI 0.67, 1.12 p=0.256). 
Celokupno preživetje se po končni analizi, opravljeni potem, ko se je pojavilo 76 % (280/369) dogodkov (razmerje ogroženosti 0,87, 95 % IZ 0,67; 1,12, p = 0,256), med terapevtskima krakoma ni značilno razlikovalo.
No dose adjustment is required in patients with creatinine clearance above 30 ml/min. 
Pri bolnikih s kreatininskim očistkom, večjim od 30 ml/min, odmerka ni treba prilagajati.
Each film-coated tablet contains 400 mg pazopanib (as hydrochloride). 
Ena filmsko obložena tableta vsebuje 400 mg pazopaniba (v obliki pazopanibijevega klorida).
Reversal of effects of TMA has been observed after treatment was discontinued. 
Po ukinitvi zdravljenja so opažali izginotje učinkov TMA.
Tablet coating Hypromellose Iron oxide red (E172) Macrogol 400 
Obloga tablete hipromeloza rdeči železov oksid (E172) makrogol 400 polisorbat 80 titanov dioksid (E171)
The most important serious adverse reactions identified in the RCC or STS studies were transient ischaemic attack, ischaemic stroke, myocardial ischaemia, myocardial and cerebral infarction, cardiac dysfunction, gastrointestinal perforation and fistula, QT prolongation, Torsade de Pointes and pulmonary, gastrointestinal and cerebral haemorrhage, all adverse reactions being reported in <1% of treated patients. 
Najpomembnejši resni neželeni učinki, ugotovljeni v študijah pri RCC in STS, so bili tranzitorna ishemična ataka, ishemična kap, miokardna ishemija, miokardni in cerebralni infarkt, diskfunkcija srca, gastrointestinalna perforacija in fistula, podaljšanje intervala QT, torsades de pointes ter krvavitve v pljučih, prebavilih in možganih.
Stop taking Votrient and seek medical help immediately if you develop hypertensive crisis. 
Če se pri vas pojavi hipertenzivna kriza, prenehajte z jemanjem zdravila Votrient in takoj poiščite zdravniško pomoč.
The median steady-state pazopanib Cmax and AUC(0-24) in patients with mild abnormalities in hepatic parameters (defined as either normal bilirubin and any degree of ALT elevation or as an elevation of bilirubin up to 1.5 x ULN regardless of the ALT value) after administration of 800 mg once daily are similar to the median in patients with normal hepatic function (see Table 7). 
Mediani Cmax in AUC(0-24) v stanju dinamičnega ravnovesja pri bolnikih z blagimi nepravilnostmi jetrnih parametrov (opredeljenimi bodisi kot normalen bilirubin in kakršno koli zvišanje alaninaminotransferaze (ALT) bodisi kot zvišanje bilirubina do 1,5-kratne ZMN ne glede na vrednost ALT) po uporabi 800 mg enkrat na dan sta podobni medianama pri bolnikih z normalnim delovanjem jeter (glejte preglednico 7).
Symptoms include: - passing blood in the stools or passing black stools - passing blood in the urine - stomach pain - coughing or vomiting up blood 
Simptomi teh krvavitev so lahko: - kri v blatu ali črno blato, - kri v urinu, - bolečina v želodcu, - izkašljevanje ali bruhanje krvi.
Symptoms of infections may include: - fever - flu-like symptoms such as cough, tiredness and body aches that do not go away - shortness of breath and/or wheezing - pain while urinating - cuts, scrapes or wounds that are red, warm, swollen or painful Seek medical help immediately if you get any of these symptoms. 
Simptomi okužbe lahko vključujejo: - zvišano telesno temperaturo, - simptome, ki spominjajo na gripo, kot so kašelj, utrujenost in bolečine po telesu, ki ne izginejo, - kratka sapa in/ali piskanje v prsih, - bolečina pri uriniranju, - ureznine, praske ali rane, ki so pordele, tople, otekle ali boleče.
Signs and symptoms may include: - bruising easily - high blood pressure - fever - confusion - drowsiness - seizures (fits) - decrease in urine output 
Znaki in simptomi lahko vključujejo: - hiter nastanek modric, - visok krvni tlak, - zvišano telesno temperaturo, - zmedenost, - dremavost, - epileptični napad (krče), - zmanjšano izločanje urina.
Therefore, inhibitors and inducers of CYP3A4 may alter the metabolism of pazopanib. 
Zaviralci in induktorji CYP3A4 torej lahko vplivajo na presnovo pazopaniba.
Administration of pazopanib with a high-fat or low-fat meal results in an approximately 2-fold increase in AUC and Cmax. 
Pri uporabi pazopaniba skupaj z obrokom z veliko ali majhno vsebnostjo maščob sta se vrednosti AUC in Cmax pazopaniba povečali za približno 2-krat.
Blood and lymphatic system disorders f 
Bolezni krvi in limfatičnega sistema f zelo pogosti levkopenija trombocitopenija 86
Interrupt pazopanib until transaminases return to Grade 1 or baseline. 
Prekinite zdravljenje s pazopanibom, dokler se aminotransferaze ne vrnejo na stopnjo 1 ali izhodiščno vrednost.
800 mg OD 
800 mg 1x na dan
Systemic exposure to pazopanib is increased when administered with food. 
Pri uporabi pazopaniba skupaj s hrano se sistemska izpostavljenost pazopanibu poveča.
Each film-coated tablet contains 200 mg pazopanib (as hydrochloride). 
Ena filmsko obložena tableta vsebuje 200 mg pazopaniba (v obliki pazopanibijevega klorida).
Very common Tumour pain 
zelo pogosti tumorska bolečina 121
Pazopanib did not cause genetic damage when tested in genotoxicity assays (Ames assay, human peripheral lymphocyte chromosome aberration assay and rat in vivo micronucleus). 
Pazopanib pri testih genotoksičnosti (Amesov test, test kromosomskih aberacij na humanih perifernih limfocitih ter in vivo mikronukleusni test pri podganah) ni povzročal genetskih poškodb.
Votrient is not recommended if you are pregnant. 
Med nosečnostjo uporaba zdravila Votrient ni priporočljiva.
Your doctor will be checking your liver enzymes while you are taking Votrient. 
Med zdravljenjem z zdravilom Votrient bo zdravnik nadzoroval vaše jetrne encime.
Patients who carry the HLA-B*57:01 allele have an increased risk of pazopanib-associated ALT elevations. 
Tveganje za zvišanje vrednosti ALT zaradi pazopaniba je lahko povečano tudi pri bolnikih, ki so nosilci alela HLA-B*57:01.
Mild, indirect (unconjugated) hyperbilirubinaemia may occur in patients with Gilbert's syndrome. 
Pri bolnikih z Gilbertovim sindromom se lahko pojavi blaga indirektna (nekonjugirana) hiperbilirubinemija.
In clinical studies with pazopanib, myocardial infarction, myocardial ischaemia, ischaemic stroke and transient ischaemic attack were observed (see section 4.8). 
V kliničnih študijah s pazopanibom so poročali o pojavu miokardnega infarkta, miokardne ishemije, ishemične kapi in tranzitorne ishemične atake (glejte poglavje 4.8).
Patients developing TMA should permanently discontinue treatment with pazopanib. 
Bolniki, ki se jim pojavi TMA, morajo trajno prenehati z zdravljenjem s pazopanibom.
There was no consistent increase in AUC or Cmax at pazopanib doses above 800 mg. 
Pri odmerkih pazopaniba, večjih od 800 mg, ni konsistentnega povečanja vrednosti AUC ali Cmax.
Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor (PDGFR) -α and -β, and stem cell factor receptor (c-KIT), with IC50 values of 10, 30, 47, 71, 84 and 74 nM, respectively. 
Je močan multitarčni zaviralec tirozin kinaznih (TKI - tyrosine kinase inhibitor) receptorjev za žilni endotelijski rastni faktor (VEGFR - Vascular Endothelial Growth Factor Receptors)-1, -2 in -3, trombocitni rastni faktor (PDGFR - platelet-derived growth factor)-α in -β, ter receptorje za faktor matičnih celic (stem cell factor receptor; (c-KIT).
Common side effects (may affect up to 1 in 10 people): - indigestion, bloating, flatulence - nose bleed - dry mouth or mouth ulcers - infections - abnormal drowsiness - difficulty sleeping - chest pain, shortness of breath, leg pain, and swelling of the legs/feet. 
Pogosti neželeni učinki (lahko se pojavijo pri največ 1 od 10 bolnikov): - prebavne težave, napihnjenost, nabiranje plinov v črevesu, - krvavitev iz nosu, - suha usta ali razjede v ustih, - okužbe, - nenormalna zaspanost, - motnje spanja, - bolečina v prsih, kratka sapa, bolečine v nogah in oteklost nog/stopal.
Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and close monitoring of tolerability. 
Pri bolnikih z blago ali zmerno okvaro jeter je treba pazopanib uporabiti previdno in skrbno nadzirati prenašanje.
Administration of pazopanib to patients with mild or moderate hepatic impairment should be undertaken with caution and close monitoring. 
Pri bolnikih z blago do zmerno okvaro jeter je treba pazopanib uporabljati previdno in ob natančnem spremljanju.
Seek medical help immediately if you get any of these symptoms. 
Če se pri vas pojavi kateri od teh simptomov, takoj poiščite zdravniško pomoč.
30 film-coated tablets 90 film-coated tablets 
filmsko obložena tableta 30 filmsko obloženih tablet 90 filmsko obloženih tablet
Take it at least two hours after a meal, or one hour before a meal. 
Zdravilo Votrient vzemite vsaj dve uri po jedi ali eno uro pred jedjo.
Each Votrient 200 mg film-coated tablet contains 200 mg pazopanib. 
Ena Votrient 200 mg filmsko obložena tableta vsebuje 200 mg pazopaniba.
150 mg/m resulted in an approximately 20% increase in systemic exposure to SN-38. 
Sočasna uporaba 400 mg pazopaniba enkrat na dan z 250 mg/m cetuksimaba in 150 mg/m irinotekana je povečala sistemsko izpostavljenost presnovku SN-38 za približno 20 %.
Rare side effects (may affect up to 1 in 1,000 people): - inflammation of the lung (pneumonitis) 
Redki neželeni učinki (lahko se pojavijo pri največ 1 od 1.000 bolnikov):
Not all pack sizes or tablet strengths may be available in your country. 
Na trgu morda ni vseh navedenih pakiranj ali jakosti zdravila.
PRES/RPLS has been reported in association with pazopanib. 
V povezavi s pazopanibom je bil opisan PRES/RPLS.
- Tell your doctor if you have high blood pressure. 
- Če imate visok krvni tlak, o tem obvestite svojega zdravnika.
Approximately half of all patients had 3 or more organs involved in their disease and most patients had the lung (74%), and/or lymph nodes (54%) as a metastatic location for disease at baseline. 
V izhodišču so bile metastaze pri večini bolnikov prisotne v pljučih (74 %) in/ali bezgavkah (54 %).
- Avoid driving or using machines if you feel dizzy, tired or weak, or if your energy levels are low. 
- Če ste omotični, utrujeni, oslabeli ali brez energije, ne smete upravljati z vozili ali stroji.
x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 290) Median 9.2 months; Placebo ------- (N = 145) Median 4.2 months; Hazard Ratio = 0.46, 95% CI (0.34, 0.62), P <0.0000001 
os x: meseci, os y: delež brez napredovanja, Pazopanib --- (n = 290) mediana 9,2 meseca, Placebo -------(n = 145) mediana 4,2 meseca, Razmerje tveganj = 0,46, 95 % IZ (0,34; 0,62), P < 0,0000001
Pharmacokinetic parameter comparisons of pazopanib Cmax (range of means 27.5 to 58.1 µg/ml) and AUC(0-24) (range of means 48.7 to 1040 µg*h/ml) after administration of pazopanib 800 mg alone and after administration of pazopanib 400 mg plus ketoconazole 400 mg (mean Cmax 59.2 µg/ml, mean AUC(0-24)1300 µg*h/ml) indicated that, in the presence of a strong CYP3A4 and P-gp inhibitor a dose reduction to pazopanib 400 mg once daily will, in the majority of patients, result in systemic exposure similar to that observed after administration of 800 mg pazopanib once daily alone. 
Opravili so primerjave farmakokinetičnih parametrov pazopaniba Cmax (razpon povprečij od 27,5 do 58,1 µg/ml) in AUC(0-24) (razpon povprečij od 48,7 do 1040 µg*h/ml) po uporabi 800 mg pazopaniba samega in po uporabi 400 mg pazopaniba s 400 mg ketokonazola (povprečna Cmax 59,2 µg/ml, povprečna AUC(0-24) 1300 µg*h/ml).
Each Votrient 400 mg film-coated tablet contains 400 mg pazopanib. 
Ena Votrient 400 mg filmsko obložena tableta vsebuje 400 mg pazopaniba.
The maximally tolerated pazopanib dose (MTD) in patients with moderate hepatic impairment (defined as an elevation of bilirubin >1.5 x to 3 x ULN regardless of the ALT values) was 200 mg once daily. 
Pri bolnikih z zmerno okvaro jeter (opredeljeno kot zvišanje bilirubina na > 1,5- do 3-kratno ZMN ne glede na vrednost ALT) je bil največji tolerirani odmerek (MTD - maximally tolerated dose) pazopaniba 200 mg enkrat na dan.
Pazopanib has been shown to be embryotoxic and teratogenic when administered to rats and rabbits at exposures more than 300-fold lower than the human exposure (based on AUC). 
Pri podganah in kuncih je pazopanib pri izpostavljenosti, ki je bila več kot 300-krat manjša od izpostavljenosti človeka (na osnovi AUC), deloval embriotoksično in teratogeno.
The clinical status of the patient and the adverse event profile of pazopanib should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor or cognitive skills. 
Pri presojanju bolnikove sposobnosti za opravila, ki zahtevajo presojo motorične ali kognitivne funkcije, je treba upoštevati tako klinično stanje bolnika kot profil neželenih učinkov pazopaniba.
Mild 
Zmerna
Votrient 400 mg film-coated tablets are capsule-shaped, white with “GS UHL” marked on one side. 
Votrient 400 mg filmsko obložene tablete Bele filmsko obložene tablete v obliki kapsule z oznako GS UHL na eni strani.
Transaminase elevation of >8 x ULN 
Zvišanje vrednosti aminotransferaz na > 8-kratno ZMN
x axis; Months, y axis; Proportion Progression Free, Pazopanib --- (N = 155) Median 11.1 months; Placebo -------- (N = 78) Median 2.8 months; Hazard Ratio = 0.40, 95% CI (0.27, 0.60), P <0.0000001 
os x: meseci, os y: delež brez napredovanja, Pazopanib --- (n = 155) mediana 11,1 meseca, Placebo-------(n = 78) mediana 2,8 meseca, Razmerje tveganj = 0,40, 95 % IZ (0,27; 0,60), P < 0,0000001
The film-coated tablets should be taken whole with water and not broken or crushed (see section 5.2). 
Ne sme jih razpolavljati ali zdrobiti (glejte poglavje 5.2).
Administration of 1500 mg lapatinib (a substrate for and weak inhibitor of CYP3A4 and P-gp and a potent inhibitor of BCRP) with 800 mg pazopanib resulted in an approximately 50% to 60% increase in mean pazopanib AUC(0-24) and Cmax compared to administration of 800 mg pazopanib alone. 
Pri uporabi lapatiniba (ki je substrat in šibek zaviralec CYP3A4 in P-gp ter močen zaviralec BCRP) v odmerku 1500 mg skupaj s pazopanibom v odmerku 800 mg, sta se srednji vrednosti AUC(0-24) in Cmax pazopaniba povečali za približno od 50 % do 60 % v primerjavi z uporabo pazopaniba samega v odmerku 800 mg. Zavrtje P-gp in/ali BCRP z lapatinibom je verjetno pripomoglo k večji izpostavljenosti pazopanibu.
TMA has been reported in clinical studies of pazopanib as monotherapy, in combination with bevacizumab, and in combination with topotecan (see section 4.8). 
V kliničnih študijah, v katerih so preučevali pazopanib v monoterapiji, v kombinaciji z bevacizumabom oziroma v kombinaciji s topotekanom, je bila opisana TMA (glejte poglavje 4.8).